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The World Health Organization estimates that about 3%
of the world population is infected with HCV and 3 mil-
lion individuals are infected each year. Most of those
infected develop chronic liver disease leading, in some
cases, to liver failure or hepatocellular carcinoma.
Little information is available on the epidemiology, natu-
ral history and responsiveness to antiviral therapy of HCV
infection in children. The epidemiology has changed sub-
stantially in recent years. In Italy, for example, in the 90's
most children were affected by post-transfusional hepati-
tis. In contrast, in the new millennium most have been
due to mother-to-child transmission. The total number of
vertically infected children has also been decreasing,
because the screening of blood donors has reduced the
spread of the virus to women of child-bearing age. How-
ever, in the USA approximately 7000 new cases of vertical
infection are estimated to occur over the next decade. The
screening of blood donors has also changed the relative
prevalence of different genotypes in infected children,
with a decrease in transfusion-associated type 1b geno-
type and an increased percentage of genotypes 3 and 4;
this has relevant therapeutic implications since the latter
are more sensitive to specific treatment. Newer popula-
tion-based studies on the epidemiology of paediatric
infection in different parts of the world are needed.
During primary infection no vertically infected infant
becomes icteric or developed signs. Interesting, only one
third of infected infants are viraemic at birth. The PCR
assay proved highly specific with a good sensitivity (about
80%) from the first month of life. Based on the presence
of viraemia over time, three groups of vertically infected
children can be identified: a) with persistent viraemia, b)
with intermittent viraemia, and c) seropositive children in
whom serum HCV RNA was never detected. At times, chil-
dren with intermittent viraemia may be PCR-negative but
with increased ALT levels. Initially, ALT levels mirror a pri-
mary infection that is normal or mildly enhanced values
during the first months of life, with a subsequent increase.
ALT concentrations decline after the first two years of life,
presumably reflecting better viral control by a more effec-
tive adaptive response after infancy. Overall, the enhance-
ment of ALT levels was less frequent and pronounced than
in adults.
HCV-associated clinical manifestations were observed in a
minority of vertically infected children, with only a quar-
ter developing hepatomegaly in the first decade. Further-
more, all children grew regularly, with no variations from
the normal height and weight ranges. A high frequency of
autoantibodies has been reported also in childhood,
although with the bias of a selected population recruited
by tertiary care centres, while the incidence of autoim-
mune reactions in vertical chronic infection remains to be
established.
Wide ranges of histopathologic abnormalities have been
found in children with vertical infection. Although to dif-
ferent extents, most patients had signs of chronic hepati-
tis. Based on signs of structural alterations, inflammatory
activity, and necrosis the grade of disease usually varies
from minimal to moderate, though some children have a
certain degree of fibrosis. No direct correlation was found
between underlying liver disease and increased ALT levels,
suggesting that these are not accurate prognostic markers.
Some cases of advanced liver disease in infected children
have however been described, including the need for liver
transplantation. In general, patient and allograft survival
are suboptimal in transplanted children with chronic
HCV infection, with a high risk of recurrence requiring re-
tranplantation with a poor prognosis.
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Taken together the data suggest that about 20% of verti-
cally infected children, being repeatedly PCR negative the
last times they were tested, with no symptoms or ALT
abnormalities, apparently recover from infection. Half of
the children remain asymptomatic with chronic infection,
fluctuations of viraemia and ALT activity. The remaining
30% have chronic active infection with persistent virae-
mia, abnormal ALT activity and, sometimes, hepatomeg-
aly. Among these a fraction may develop severe liver
damage.
This heterogeneity in disease progression implies the
existance of virus-related and/or host-related factors con-
ditioning the liver injury, which require specific research.
Most studies agree that genotypes and viral load do not
have a significant impact on the evolution of infection,
although some authors suggest a worse outcome with
genotype 1. Several investigations focused on the diversi-
fication of HCV quasispecies in vertically infected chil-
dren. In general, only one or a low number of variants are
present in the first months of life, then seroconversion
leads to the development of many quasispecies. The pres-
sure due to the humoral response is consistent with the
low or no viral diversification observed in hypogamma-
globulinemic subjects, who have severe disease progres-
sion. In one study, biochemical evidence of hepatic injury
was invariably associated with a mono- or oligoclonal
viral population, whereas mild or no liver damage corre-
lated with the early emergence of many viral variants.
As far as host-related factors on HCV progression are con-
cerned, many immunologic alterations in both PBMCs
and in the liver have been described. However, these find-
ings mostly seem secondary to the chronic infection rather
than being responsible for its evolution.
In conclusion, vertically-acquired HCV infection is char-
acterized by a high chronicity rate, but mild liver injury for
most of those infected. This supports the hypothesis that
the hepatocellular insult is not due to the direct cytopathic
effects of HCV, but rather to the virus-driven immune
response. The less vigorous reaction of the immune sys-
tem in the first years of life may be insufficient to eradicate
the virus completely, although it may account for the
lower liver damage. The virus interacts with the immune
system to guarantee its survival, but, unlike HIV, it leaves
the host free to control other infections. Given the lack of
clinical manifestations, children with chronic HCV infec-
tion may remain undiagnosed until the late appearance of
symptoms and signs in adolescence or adulthood, when
therapeutic interventions may less efficiently prevent or
eliminate long-lasting liver damage.Page 2 of 2
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